Lyell Immunopharma, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · South San Francisco, CA
LYEL chart
What traders are saying about $LYEL
Latest postsLyell Immunopharma, Inc. news
- Lyell Immunopharma, Inc. Estimates – NASDAQ:LYEL
TradingView ·
- We're Keeping An Eye On Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Rate
Simply Wall Street ·
- Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Yahoo Finance ·
- Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
Yahoo Finance ·
- Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Yahoo Finance ·
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
Yahoo Finance ·
- Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Yahoo Finance ·
- Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
247wallst.com ·
- AbCellera Appoints Dr. Lynn Seely to its Board of Directors
Yahoo Finance ·
- Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
Yahoo Finance ·
- Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Yahoo Finance ·
- Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Yahoo Finance ·
Lyell Immunopharma, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $36,000 | $61,000 | $130,000 | $84.7M |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M |
| Diluted EPS | $-16.06 | $-26.23 | $-18.70 | $-0.74 |
| Total assets (year end) | $340.1M | $490.9M | $750.0M | $937.6M |
| Cash and equivalents (year end) | $60.2M | $105.6M | $145.6M | $123.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Lyell Immunopharma, Inc.
- Ticker
- LYEL (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1806952
Frequently asked questions
What exchange is Lyell Immunopharma, Inc. listed on?
Lyell Immunopharma, Inc. trades on the Nasdaq under the ticker symbol LYEL.
What industry is Lyell Immunopharma, Inc. in?
Lyell Immunopharma, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Lyell Immunopharma, Inc. headquartered?
Lyell Immunopharma, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Lyell Immunopharma, Inc.'s fiscal year end?
Lyell Immunopharma, Inc.'s fiscal year ends on December 31.
How much revenue did Lyell Immunopharma, Inc. report?
Lyell Immunopharma, Inc. reported $36,000 in revenue for calendar year 2025, according to its SEC filings.